Literature DB >> 16118497

Posterior reversible encephalopathy complicating intravenous immunoglobulins in a patient with miller-fisher syndrome.

Masashi Nakajima1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16118497     DOI： 10.1159/000087720

Source DB:  PubMed          Journal:  Eur Neurol        ISSN： 0014-3022            Impact factor:   1.710


× No keyword cloud information.
  6 in total

1.  Minimally symptomatic posterior reversible encephalopathy in Guillain-Barré syndrome.

Authors:  Giovanni Piccolo; Giuseppina Borutti; Diego Franciotta; Carla Arbasino; Carlo Dallocchio; Claudia Camana; Giada Gola; Maria Grazia Egitto
Journal:  Funct Neurol       Date:  2015 Jan-Mar

2.  Lysergic acid amide-induced posterior reversible encephalopathy syndrome with status epilepticus.

Authors:  Stephane Legriel; Fabrice Bruneel; Odile Spreux-Varoquaux; Aurelie Birenbaum; Marie Laure Chadenat; François Mignon; Nathalie Abbosh; Matthieu Henry-Lagarrigue; Laure Revault D'Allonnes; Pierre Guezennec; Gilles Troche; Jean Pierre Bedos
Journal:  Neurocrit Care       Date:  2008       Impact factor: 3.210

Review 3.  Is passive immunization for Alzheimer's disease 'alive and well' or 'dead and buried'?

Authors:  Gregory A Jicha
Journal:  Expert Opin Biol Ther       Date:  2009-04       Impact factor: 4.388

Review 4.  Autonomic involvement in Guillain-Barré syndrome: an update.

Authors:  Zoya Zaeem; Zaeem A Siddiqi; Douglas W Zochodne
Journal:  Clin Auton Res       Date:  2018-07-17       Impact factor: 4.435

5.  Posterior reversible encephalopathy as the first manifestation of Bickerstaff's brainstem encephalitis.

Authors:  Pei-Ru Chen; Shih-Pin Chen
Journal:  BMC Neurol       Date:  2016-11-08       Impact factor: 2.474

Review 6.  Adverse Effects of Immunoglobulin Therapy.

Authors:  Yi Guo; Xin Tian; Xuefeng Wang; Zheng Xiao
Journal:  Front Immunol       Date:  2018-06-08       Impact factor: 7.561
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.